418 related articles for article (PubMed ID: 11992244)
1. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease.
Schwarz HP; Schlokat U; Mitterer A; Váradi K; Gritsch H; Muchitsch EM; Auer W; Pichler L; Dorner F; Turecek PL
Semin Thromb Hemost; 2002 Apr; 28(2):215-26. PubMed ID: 11992244
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
3. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
[TBL] [Abstract][Full Text] [Related]
5. Development of a plasma- and albumin-free recombinant von Willebrand factor.
Turecek PL; Mitterer A; Matthiessen HP; Gritsch H; Varadi K; Siekmann J; Schnecker K; Plaimauer B; Kaliwoda M; Purtscher M; Woehrer W; Mundt W; Muchitsch EM; Suiter T; Ewenstein B; Ehrlich HJ; Schwarz HP
Hamostaseologie; 2009 Oct; 29 Suppl 1():S32-8. PubMed ID: 19763356
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro processing of recombinant pro-von Willebrand factor.
Turecek PL; Váradi K; Schlokat U; Pichler L; Dorner F; Schwarz HP
Histochem Cell Biol; 2002 Feb; 117(2):123-9. PubMed ID: 11935288
[TBL] [Abstract][Full Text] [Related]
8. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
9. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease.
Turecek PL; Pichler L; Auer W; Eder G; Varadi K; Mitterer A; Mundt W; Schlokat U; Dorner F; Drouet LO; Roussi J; van Mourik JA; Schwarz HP
Blood; 1999 Sep; 94(5):1637-47. PubMed ID: 10477688
[TBL] [Abstract][Full Text] [Related]
10. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
12. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
Neugebauer BM; Goy C; Budek I; Seitz R
Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
[TBL] [Abstract][Full Text] [Related]
15. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice.
Schwarz HP; Lenting PJ; Binder B; Mihaly J; Denis C; Dorner F; Turecek PL
Blood; 2000 Mar; 95(5):1703-8. PubMed ID: 10688827
[TBL] [Abstract][Full Text] [Related]
16. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
[TBL] [Abstract][Full Text] [Related]
17. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
Hilbert L; Nurden P; Caron C; Nurden AT; Goudemand J; Meyer D; Fressinaud E; Mazurier C;
Thromb Haemost; 2006 Sep; 96(3):290-4. PubMed ID: 16953269
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
Turecek PL; Siekmann J; Schwarz HP
Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.
Turecek PL; Gritsch H; Richter G; Auer W; Pichler L; Schwarz HP
Thromb Haemost; 1997 Mar; 77(3):591-9. PubMed ID: 9066015
[TBL] [Abstract][Full Text] [Related]
20. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
